Verzögert
Andere Börsenplätze
|
% 5 Tage | % 1. Jan. | ||
- USD | -.--% |
|
-0.07% | +269.92% |
2019 | Transcript : Dova Pharmaceuticals, Inc., Q2 2019 Earnings Call, Aug 06, 2019 | |
2019 | Transcript : Dova Pharmaceuticals, Inc. - Special Call |
Umsatz 2017 | - | Umsatz 2018 | 10.36 9.19 | Marktwert | 214 Mio. 190 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2017 | -30 Mio. -26.63 Mio. | Nettoergebnis 2018 | -72 Mio. -63.91 Mio. | EV / Sales 2017 | - |
Nettoliquidität 2017 | 64.53 Mio. 57.28 Mio. | Nettoliquidität 2018 | 84.34 Mio. 74.86 Mio. | EV / Sales 2018 | 12’500’634 x |
KGV 2017 |
-20.6
x | KGV 2018 |
-2.92
x | Beschäftigte | - |
Rendite 2017 * |
-
| Rendite 2018 |
-
| Streubesitz | 48.06% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Mahmood Ladha
PSD | President | 60 | 12.11.19 |
Lee F. Allen
CTO | Chief Tech/Sci/R&D Officer | 72 | 01.04.17 |
Marc Banjak
LAW | General Counsel | - | - |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Henrik Stenqvist
BRD | Director/Board Member | 57 | 12.11.19 |
Guido Oelkers
BRD | Director/Board Member | 59 | 12.11.19 |
Director/Board Member | 55 | 12.11.19 |
% 1. Jan. | Kap. | |
---|---|---|
+269.92% | 808 Mio. | |
+16.42% | 122 Mrd. | |
+19.02% | 113 Mrd. | |
+3.00% | 22.66 Mrd. | |
-16.20% | 21.34 Mrd. | |
-39.57% | 16.92 Mrd. | |
-11.63% | 16.68 Mrd. | |
-16.22% | 16.61 Mrd. | |
+2.68% | 13.62 Mrd. | |
+21.16% | 11.04 Mrd. |